A dynamical systems perspective on chimeric antigen receptor T-cell dosing
暂无分享,去创建一个
J. Zweit | S. Hashmi | A. Toor | J. Reed | A. Chesney
[1] S. Grupp,et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. , 2017, Blood.
[2] Daniel Li,et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. , 2017, Blood.
[3] K. Tobinai,et al. Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma , 2017, Cancer science.
[4] M. Neale,et al. Dynamical system modeling to simulate donor T cell response to whole exome sequencing-derived recipient peptides: Understanding randomness in alloreactivity incidence following stem cell transplantation , 2016, PloS one.
[5] N. Sheth,et al. Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides: Understanding Randomness In Clinical Outcomes Following Stem Cell Transplantation , 2016, bioRxiv.
[6] S. Heimfeld,et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.
[7] Christine E Brown,et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. , 2016, Blood.
[8] Daniel Li,et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.
[9] G. Buck,et al. Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity Potential In HLA-Matched and Mismatched Donor-Recipient Pairs , 2015, bioRxiv.
[10] M. Neale,et al. Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity Potential in HLA-Matched and -Mismatched Donor-Recipient Pairs. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] S. Riddell,et al. Engineering CAR-T cells: Design concepts. , 2015, Trends in immunology.
[12] M. Neale,et al. Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes. , 2015, Biology of Blood and Marrow Transplantation.
[13] S. Riddell,et al. Designing chimeric antigen receptors to effectively and safely target tumors. , 2015, Current opinion in immunology.
[14] Sadik H. Kassim,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[16] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[17] M. Neale,et al. In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic Transplantation , 2014, Front. Immunol..
[18] M. Neale,et al. Whole exome sequencing to estimate alloreactivity potential between donors and recipients in stem cell transplantation , 2014, British journal of haematology.
[19] S. Gottschalk,et al. Design and development of therapies using chimeric antigen receptor‐expressing T cells , 2014, Immunological reviews.
[20] C. Desmarais,et al. Fractal organization of the human T cell repertoire in health and after stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] Jeffrey E. Lee,et al. Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients , 2012, Clinical Cancer Research.
[22] C. June,et al. Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.